Related by context. All words. (Click for frequent words.) 75 CMV infection 71 invasive candidiasis 70 candidemia 70 venous blood clots 70 delayed CINV 69 thrombotic complications 69 recurrent VTE 69 invasive fungal infections 69 tumor recurrence 68 HCV infection 68 posaconazole 68 S. aureus infections 68 mycophenolate mofetil 68 severe rotavirus gastroenteritis 67 endophthalmitis 67 ximelagatran 67 efalizumab 67 acute GVHD 67 liver metastases 67 venous thromboembolic events 67 invasive aspergillosis 67 solid organ transplantation 67 PTLD 66 metastatic RCC 66 CMV reactivation 66 hepatitis C genotype 66 thromboembolic events 66 chronic GVHD 66 chronic HCV infection 66 HBeAg negative 66 severe neutropenia 66 thromboembolic complications 66 colorectal liver metastases 66 intracranial hemorrhage ICH 66 cytoreduction 66 R0 resection 66 intravenous bisphosphonates 66 transplantation HCT 66 atherothrombotic events 66 EXJADE 66 neoadjuvant therapy 66 HBeAg positive patients 66 chronic HBV 66 relapsed MM 66 latent tuberculosis infection 66 malignant pleural mesothelioma 66 HBV infection 66 hepatocellular carcinoma 66 distant metastases 66 hepatocellular carcinoma HCC 66 nephrotoxicity 66 mRCC 66 CMV infections 66 corticosteroid therapy 65 chlamydial infection 65 octreotide LAR 65 cisplatin chemotherapy 65 vaccine serotypes 65 pneumococcal infection 65 antimicrobial prophylaxis 65 peginterferon 65 Acute Radiation Syndrome ARS 65 TORISEL 65 recurrent glioblastoma multiforme 65 immunosuppressive therapies 65 thrombotic events 65 rFVIIa 65 metastatic GIST 65 renal transplantation 65 Candida infection 65 autologous transplants 65 upper gastrointestinal bleeding 65 contrast induced nephropathy 65 pancreatic adenocarcinoma 65 chlorambucil 65 acute GvHD 65 virologic failure 65 perioperative mortality 65 HBV infections 65 NATRECOR R 65 LTBI 65 chemoradiotherapy 65 allogeneic hematopoietic stem cell 65 calcineurin inhibitors 65 chronic HBV infection 65 allogeneic stem cell 65 imipenem 65 endometrial hyperplasia 64 FluCAM arm 64 immunocompetent 64 postoperative pulmonary 64 romiplostim 64 retransplantation 64 renal toxicity 64 S. aureus infection 64 cervical carcinoma 64 HCV infected 64 pancreatic NET 64 metastatic neuroendocrine tumors 64 nonvaccine serotypes 64 grade cervical dysplasia 64 tamoxifen therapy 64 immunosuppressed 64 Hepatocellular Carcinoma HCC 64 prostate cancer CRPC 64 prostate adenocarcinoma 64 hepatitis C HCV 64 ADPKD 64 SHPT 64 metastatic lung cancer 64 sustained virological response 64 HSCT 64 immunosuppression 64 vWD 64 gastrointestinal stromal tumors GIST 64 recurrent genital herpes 64 CTAP# Capsules 64 leukemia ALL 64 alteplase 64 NNRTI resistance 64 Torisel 64 liver resection 64 locoregional recurrence 64 chemotherapy induced neutropenia 64 perioperative complications 64 APTIVUS r 64 curative resection 64 postoperative atrial fibrillation 64 therapeutic regimens 64 DAPT 64 androgen deprivation 64 chronic periodontitis 64 HCV infections 64 PREZISTA r 64 GVHD 63 variceal bleeding 63 gastric adenocarcinoma 63 GISTs 63 renal tumors 63 ovarian carcinoma 63 Candida infections 63 cirrhosis liver failure 63 sustained virologic response 63 cerebral vasospasm 63 refractory gout 63 renal cell carcinomas 63 nonmelanoma skin cancers 63 Natalizumab 63 metastatic renal cell carcinoma 63 invasive fungal infection 63 Tavocept 63 radical nephrectomy 63 thrombocytopenic 63 acute onset CINV 63 HER2 overexpression 63 genital herpes infections 63 LCMV infection 63 revascularization procedures 63 clodronate 63 T1DM 63 radioiodine therapy 63 antibiotic prophylaxis 63 squamous cell lung cancer 63 cytomegalovirus infection 63 Doxil ® 63 hepatorenal syndrome 63 delayed onset CINV 63 RSV infection 63 oral FTY# 63 kidney transplant recipients 63 Aspergillus infections 63 Contrast Induced Nephropathy CIN 63 precursor lesions 63 lupus nephritis 63 PNH patients 63 Velcade bortezomib 63 HIV HCV coinfected 63 taxane chemotherapy 63 immunosuppressive regimens 63 VZV 63 cIAI 63 ROTARIX 63 HBsAg 63 leukemia AML 63 advanced adenoma 63 tuberculin skin testing 63 inhibitor RG# 63 PEGylated interferon beta 1a 63 complete cytogenetic response 63 TACE 63 medullary thyroid cancer 63 adalimumab 63 gastrointestinal toxicity 63 biochemical relapse 63 thromboembolic disease 63 HBeAg seroconversion 63 Adhibit 63 venous thromboembolism 63 retinal vein occlusion 63 Liver transplantation 63 CMV seropositive 63 GIST tumors 63 adult chronic ITP 63 Valcyte 63 allogeneic bone marrow 63 colorectal cancer CRC 63 metastatic malignant 63 superficial bladder cancer 63 renal dysfunction 63 paroxysmal AF 63 pegylated interferon alfa 63 metastatic kidney 63 macrovascular events 63 refractory angina 63 herpes zoster shingles 63 cobiprostone 63 PROCHYMAL 63 azacitidine 63 peritoneal cancer 63 transplantation HSCT 63 metastatic malignant melanoma 63 Glioblastoma Multiforme 63 receiving VICTRELIS 63 Surgical resection 63 hepatic metastases 63 surgical adhesions 63 curative therapy 62 recurrent glioma 62 myopathy rhabdomyolysis 62 gastrointestinal stromal tumors 62 malignant neoplasm 62 chemotherapeutic regimens 62 nitazoxanide 62 antithrombotic therapy 62 lymphocytosis 62 Aprotinin 62 hemorrhagic complications 62 recurrent wheezing 62 antiplatelet therapy 62 calcineurin inhibitor 62 TroVax ® 62 carotid artery stenting 62 teriflunomide 62 ALND 62 Noxafil 62 stage IIIB 62 Combination therapy 62 CYPHER Stent 62 viremia 62 relapsed SCLC 62 colectomy 62 heavily pretreated 62 oral RSD# 62 Hydroxyurea 62 hepatocellular cancer 62 metastatic lesions 62 BARACLUDE ® 62 CDAD 62 immunosuppressed patients 62 non squamous NSCLC 62 transfusion syndrome 62 lymph node dissection 62 Vascugel 62 severe oral mucositis 62 anthracycline taxane 62 decitabine 62 TYZEKA 62 chronic ITP 62 epithelial tumors 62 Allovectin 7 ® 62 oral rivaroxaban 62 allogeneic HSCT 62 cytomegalovirus CMV 62 cytoreductive surgery 62 rebleeding 62 nucleoside naive patients 62 unresectable tumors 62 non metastatic osteosarcoma 62 grade cervical intraepithelial 62 recurrent atrial fibrillation 62 IV NSCLC 62 seminoma 62 antiviral therapy 62 rotavirus diarrhea 62 chronic HCV 62 hypercalcemia 62 canakinumab 62 basiliximab 62 mCRC patients 62 HPV subtypes 62 chronic granulomatous disease 62 S. aureus bacteremia 62 amoxicillin clavulanate 62 ARIXTRA 62 HBV vaccine 62 carcinoid tumors 62 OHR/AVR# 62 systemic scleroderma 62 cinacalcet 62 WNV infection 62 ischemic cardiomyopathy 62 immunocompromised patients 62 chemoradiation 62 ICD implantation 62 COPD exacerbations 62 definite stent thrombosis 62 reinterventions 62 YONDELIS 62 velafermin 62 thromboembolism 62 myeloproliferative disorders 62 HER2 positive breast cancer 62 overt nephropathy 62 Adjuvant chemotherapy 62 micafungin 62 CRBSIs 62 TNF antagonist 62 pneumococcal serotypes 62 epithelial ovarian cancer 62 GvHD 62 postoperative AF 62 pegylated liposomal doxorubicin 62 locoregional 62 bevacizumab Avastin ® 62 recurrent myocardial infarction 62 cholangiocarcinoma 62 biologic DMARD 62 cervical intraepithelial neoplasia 62 infective endocarditis 62 HBV 62 advanced adenomas 62 TAXUS Stent 62 precancerous cervical lesions 62 docetaxel Taxotere ® 62 spontaneous preterm delivery 62 glucocorticoid induced osteoporosis 62 gout flares 62 recurrent venous thromboembolism 62 idraparinux 62 rotavirus gastroenteritis 62 ofpatients 62 carcinoid 62 CIMZIA ™ 61 lenalidomide Revlimid R 61 adjuvant radiation 61 Mitomycin C 61 hyperbilirubinemia 61 haematopoietic stem cell 61 allogeneic SCT 61 distant metastasis 61 ALT flares 61 basal cell nevus syndrome 61 AGHD 61 postoperative ileus 61 FOLFOX4 61 renal allograft 61 HPV-#/# 61 Myfortic 61 thoracoscopic lobectomy 61 AA Amyloidosis 61 CYT# potent vascular disrupting 61 HAART regimens 61 MELD scores 61 infliximab Remicade 61 patients evaluable 61 preoperative chemotherapy 61 disease progression 61 proliferative diabetic retinopathy 61 neuroendocrine cancers 61 GnRH agonists 61 cabazitaxel 61 cirrhotic patients 61 receiving immunosuppressive therapy 61 glycated hemoglobin levels 61 adalimumab Humira 61 KRAS status 61 PAOD 61 nucleoside analogues 61 KRAS mutations 61 complete remissions 61 MYLOTARG 61 Radical prostatectomy 61 pheochromocytoma 61 intestinal metaplasia 61 β blockers 61 ischemic complications 61 autologous SCT 61 pancreatic neuroendocrine tumors 61 adenomatous polyps 61 immunosuppressive agents 61 standard chemotherapy regimen 61 riociguat 61 SCIg 61 Hodgkin lymphoma HL 61 ribavirin therapy 61 palivizumab 61 EGFR inhibitors 61 stable angina 61 systemic lupus erythematosus SLE 61 acute humoral rejection 61 revascularization procedure 61 RSV infections 61 Raptiva r 61 tipranavir ritonavir 61 basal cell carcinoma BCC 61 BENICAR HCT 61 acute STEMI 61 proliferative retinopathy 61 post surgical adhesions 61 pelvic lymphadenectomy 61 neoplasia 61 renal scarring 61 Pentacel vaccine 61 mcg dose 61 underwent resection 61 IRX 2 61 COPD exacerbation 61 evaluable subjects 61 nonvertebral fractures 61 immunosuppressive medication 61 peritoneal carcinomatosis 61 colorectal tumors 61 gastrointestinal perforation 61 co trimoxazole 61 Vandetanib 61 relapsing MS 61 CCR5 tropic HIV 61 pneumococcal infections 61 ipsilateral stroke 61 thalidomide Thalomid 61 virologic response 61 gastrointestinal stromal tumor 61 organ transplant rejection 61 hepatitis B infection 61 immunosuppressive medications 61 FASLODEX 61 hepatectomy 61 CIMZIA TM 61 ancrod 61 Aptivus ® 61 colorectal carcinoma 61 CIN3 61 HCV genotypes 61 antiangiogenic therapy 61 adjuvant radiotherapy 61 prostate cancer CaP 61 relapsed ovarian cancer 61 HNSCC 61 tigecycline 61 erlotinib Tarceva ® 61 reinfarction 61 ZOSTAVAX 61 symptomatic aortic stenosis 61 CDI recurrence 61 graft dysfunction 61 Rasilez Tekturna 61 fluvastatin 61 CMV retinitis 61 follicular lymphomas 61 voriconazole 61 ACTEMRA TM 61 postoperative morbidity 61 5 Fluorouracil 61 seropositivity 61 Influenza vaccination 61 myelosuppression 61 Non Alcoholic Fatty 61 seroconversion 61 metastatic gastric 61 metastatic tumors 61 CsA 61 chronic rhinosinusitis 61 zoledronic acid 61 drug ISA# 61 belatacept 61 eosinophilic pneumonia 61 trastuzumab Herceptin ® 61 VTE 61 partial remissions 61 undetectable HCV RNA 61 varicella infection 61 CCyR 61 lipid lowering therapies 61 Staphylococcus aureus infections 61 enterovirus infection 61 hematologic toxicity 61 ARCOXIA 61 Bezielle 61 DVT PE 61 necrotizing pancreatitis 61 unresectable 61 CINTREDEKIN BESUDOTOX 61 nucleoside naive 61 Lung transplantation 61 pegfilgrastim 61 mapatumumab 61 heterozygous FH 61 iclaprim 61 entecavir 61 APTIVUS R 61 aldosterone antagonists 61 vaccinees 61 polyp recurrence 61 cranial irradiation 61 FROVA 61 efavirenz Sustiva 61 HeFH 61 sorafenib Nexavar 61 Severe VOD 61 Renal impairment 61 G#DT 61 sirolimus stent 61 mutated KRAS gene 61 CERVARIX 61 microvascular complications 61 lumiliximab 61 rituximab Rituxan 61 Menveo 61 deferiprone 61 TKI therapy 61 antibody titer 61 febrile neutropenia 61 KRAS mutation 61 chemoembolization 61 virological failure 61 Dasatinib 61 Thrombocytopenia 61 haematopoietic 61 Dacogen decitabine 61 hepatitis B virus HBV 61 chronic ITP patients 61 KRAS mutations occur 61 Median survival 61 samalizumab 60 HepaGam B TM 60 type 1diabetes 60 bone metastasis 60 HoFH 60 kidney urologic 60 stage IIIB IV 60 saphenous vein grafts 60 tumor resection 60 colon tumors 60 containing granisetron 60 N. gonorrhoeae 60 bendamustine 60 Metastatic breast cancer 60 postoperative delirium 60 liver transplantation 60 PRT# 60 adjuvant therapy 60 alemtuzumab treated 60 OncoVEX GM CSF 60 respiratory viral infections 60 antiplatelet medications 60 K ras mutations 60 venous thromboembolism VTE 60 letrozole Femara 60 ADHF 60 decompensated liver disease 60 GnRH agonist 60 Epstein Barr virus EBV 60 varices 60 endometriosis ovarian cysts 60 Relapsing remitting MS 60 transaminase elevations 60 HBeAg negative patients 60 dexrazoxane 60 APTIVUS ritonavir 60 ganciclovir 60 biochemical recurrence 60 reperfusion therapy 60 cystectomy 60 disease GVHD 60 Elitek 60 hepatic toxicity 60 indolent NHL 60 anemia hemoglobin 60 Eculizumab 60 renal flares 60 postoperative chemotherapy 60 nonsmall cell lung cancer 60 soft tissue sarcomas 60 arterial thromboembolic events 60 Gliadel Wafer 60 CR nPR 60 immunosuppressive therapy 60 pneumococcal pneumonia 60 Certican 60 elevated ALT 60 EBRT 60 Vectibix monotherapy 60 BCG refractory 60 recurrent GBM 60 Catheter ablation 60 aromatase inhibitor therapy 60 idiopathic pulmonary fibrosis IPF 60 cardiogenic shock 60 hematopoietic cancers 60 Toxicities 60 metastatic disease 60 complete cytogenetic 60 warfarin therapy 60 Febrile neutropenia 60 docetaxel chemotherapy 60 fibrinolysis 60 debulking surgery 60 heavily pretreated patients 60 KRAS wild 60 Gleevec resistant 60 skeletal metastases 60 herpes zoster 60 vinorelbine 60 idarubicin 60 CANCIDAS 60 recurrent miscarriage 60 radiochemotherapy 60 resected pancreatic cancer 60 juvenile idiopathic arthritis JIA 60 imatinib therapy 60 macroalbuminuria 60 ROTATEQ 60 platelet reactivity 60 MAGE A3 ASCI 60 Islet transplantation 60 trastuzumab 60 poor metabolizers 60 serotype #A 60 HAV infection 60 adenoma 60 fallopian tube carcinoma 60 LHRH antagonists 60 neoadjuvant treatment 60 postoperative nausea 60 esophageal cancers 60 myeloproliferative neoplasms 60 seroprotection 60 secondary hyperparathyroidism 60 differentiated thyroid 60 neoadjuvant chemotherapy 60 recurrent NSCLC 60 Rectal cancer 60 idiopathic myelofibrosis 60 nonvaccine 60 NATRECOR ® 60 protease inhibitor PI 60 ARCALYST ® 60 gastrointestinal cancers 60 TEAEs 60 quadrivalent vaccine 60 variceal hemorrhage 60 antibody titers 60 evaluable 60 Gleevec imatinib 60 carotid endarterectomy 60 intracerebral hemorrhage 60 acute coronary syndromes ACS 60 elacytarabine 60 allogeneic transplants 60 VFEND 60 myeloablative 60 dose cohort 60 arterial calcification 60 cytotoxic chemotherapy 60 Bacillus Calmette Guerin BCG 60 fluconazole 60 aortic valve stenosis 60 genotypic resistance 60 NAbs 60 GRNOPC1 cells 60 Chronic HCV 60 venous thrombosis 60 TYGACIL 60 acute myelogenous leukemia AML 60 durable remissions 60 REMICADE ® 60 resectable 60 4CMenB 60 NeuroStar TMS Therapy 60 Herceptin trastuzumab 60 antiretroviral naive 60 venous thromboembolisms 60 neurologic complications 60 liver transplant recipients 60 pain palliation 60 pegylated interferon alpha 60 cardiac toxicity 60 sarcomatoid 60 ImmuKnow 60 acute leukemias 60 primary hyperparathyroidism 60 nanoviricide drug 60 LC#m# 60 serogroup C 60 NOXAFIL 60 adefovir 60 cutaneous squamous cell carcinoma 60 external beam radiotherapy 60 NNT = 60 latent TB infection 60 intraoperative complications 60 Traficet EN 60 neurological complications 60 autologous hematopoietic stem cell 60 relapsing remitting 60 clevidipine 60 post thrombotic syndrome 60 pimecrolimus 60 nosocomial pneumonia 60 plus dexamethasone 60 bladder carcinoma 60 HCV genotype 60 malignant growths 60 sipuleucel T 60 pericardial effusion 60 grade dysplasia 60 interferon beta therapy 60 ZYVOX 60 myeloproliferative diseases 60 dacarbazine 60 metastatic carcinoid tumors 60 TransVax TM 60 staphylococcal infections 60 nasopharyngeal carcinoma 60 infliximab 60 basal cell carcinomas 60 direct thrombin inhibitors 60 EGFR mutations 60 myelodysplastic myeloproliferative diseases 60 bacteraemia 60 nucleotide analog 60 thromboses 60 interferon alfa 2b 60 OPAXIO 60 cytogenetic response 60 cervical lesions 60 Navelbine ® 60 breast cancer recurrence 60 immunodeficiency disorders 60 hypereosinophilic syndrome 60 H. pylori eradication 60 amphotericin B 60 arterial thrombosis 60 oral leukoplakia 60 HBeAg 60 temsirolimus 60 nonmetastatic 60 histologies 60 pneumococcal strains 60 vandetanib 60 allogeneic hematopoietic cell 60 prospectively defined 60 Gleevec imatinib mesylate 60 cisplatin gemcitabine 60 cidofovir 60 neointimal hyperplasia 60 metastatic castration resistant 60 daptomycin 60 perioperatively 60 irinotecan chemotherapy 60 XIENCE V PROMUS Stent 60 refractory AML 60 octreotide 60 interferon therapy 60 NSAID therapy 60 malignant polyps 60 GPIIb IIIa 60 systemic corticosteroid 60 portal vein thrombosis 60 virological response 60 trimethoprim sulfamethoxazole 60 Cloretazine 60 idiopathic thrombocytopenic purpura ITP 60 EBV infection 60 tocilizumab 60 Lupus nephritis 60 investigational monoclonal antibody 60 Nilotinib 60 variceal 60 imatinib resistance 60 HER2 positive cancers 60 AA amyloidosis 60 postoperative infection 60 lymphadenectomy 60 bronchopulmonary dysplasia 60 hematopoietic cell 60 leukoreduction 60 immunosuppressant therapy 60 HCV genotype 1 60 serum phosphate 60 myelodysplastic syndromes MDS 60 YERVOY 60 hepatic failure 60 atopic disease 60 locoregional disease 60 pancreatic islet cell 60 oncogenic HPV 60 minimally symptomatic metastatic castrate 59 antiplatelet drugs 59 bowel resection 59 angiographic outcomes 59 lesinurad 59 interferon alfa 59 CP CPPS 59 stem cell engraftment 59 Pegasys peginterferon alfa 2a 59 rilonacept 59 rotavirus infection 59 recurrent glioblastoma 59 IV bisphosphonates 59 EUS FNA 59 protease inhibitors PIs 59 Lubiprostone 59 severe sepsis 59 herpes infection 59 DETROL LA 59 recurrent ovarian cancer 59 pCR 59 antiretroviral naïve 59 refractory chronic myeloid 59 Vicinium TM 59 external genital lesions 59 severe aortic stenosis 59 Cytoxan 59 allogeneic transplantation 59 immune reconstitution 59 oral anticoagulation 59 adenocarcinomas 59 INVEGA ® 59 empiric therapy 59 edifoligide 59 de novo kidney transplant 59 colorectal adenoma 59 glufosfamide 59 Tumor shrinkage 59 DU #b 59 gastrointestinal stromal tumor GIST 59 metastatic prostate cancer 59 neoadjuvant 59 achieved ACR# 59 Aortic stenosis 59 operable breast cancer 59 peginterferon alfa 2a 59 dose cytarabine 59 relapsed ALL 59 adjuvant therapies 59 systemic fungal infections 59 TEMODAL 59 keloid scarring 59 systemic toxicity 59 Cethromycin 59 cytogenetic responses 59 colorectal adenomas 59 MULTAQ 59 NNRTIs 59 Fludara 59 colorectal cancer liver metastases 59 bacteremia 59 lichen planus 59 reperfusion injury 59 endometrial carcinoma 59 underwent liver transplantation 59 clinically localized prostate 59 Partial Responses 59 virus HCV infection 59 endocrine therapies 59 cardiac dysfunction 59 myocardial ischemia 59 ductal cancer 59 postoperative mortality 59 eculizumab therapy 59 Elacytarabine 59 tumor lysis syndrome 59 beta blocker therapy 59 fulvestrant 59 cervical vaginal 59 KRAS mutant tumors 59 FOLFIRI alone 59 Genital herpes 59 ductal breast cancer 59 elective PCI 59 SSc 59 FTY# 59 VTEs 59 MGUS 59 docetaxel Taxotere 59 trabectedin 59 MGd 59 thromboprophylaxis 59 neuroendocrine tumors 59 essential thrombocythemia 59 anthracycline containing 59 axillary node 59 severe hyperbilirubinemia 59 Renal Cell Carcinoma RCC 59 NEUMUNE 59 receiving VELCADE 59 bronchogenic carcinoma 59 Acute myeloid leukemia 59 nonischemic 59 chlamydial infections 59 ano genital warts 59 PCV# 59 dasatinib Sprycel ® 59 PASI scores 59 oral vancomycin 59 combination antiretroviral therapy 59 osteoporotic fractures 59 thrombolytics 59 cardioembolic stroke 59 Cholangiocarcinoma 59 VUR 59 Virulizin ® 59 Postoperative complications 59 lamivudine 59 Sezary syndrome 59 chlamydial 59 PEG interferon 59 elevated CRP 59 mesalamine granules 59 antithrombotics 59 arteriovenous access 59 Clostridium difficile infections 59 premalignant lesions 59 squamous histology 59 leukocyte count 59 NMIBC 59 dyslipidaemia 59 venous thromboembolic disease 59 advanced hepatocellular carcinoma 59 Hurthle cell 59 tipranavir 59 gonococcal infections 59 mycophenolate 59 demonstrated antitumor activity 59 palliative radiotherapy 59 ADVEXIN therapy 59 immunomodulatory therapy 59 ß blockers 59 FOLFOX 59 valent vaccine 59 Erythropoietic therapies may 59 severe hypersensitivity reactions 59 systemic corticosteroids 59 MRSA colonization 59 Pegylated interferon 59 talactoferrin 59 TMP SMX 59 lomitapide 59 pyrazinamide 59 refractory NSCLC 59 tafamidis 59 severe asthma exacerbations 59 seropositive patients 59 tumor xenograft models 59 hepatoma 59 advanced neoplasia 59 angiographic restenosis 59 microbiological eradication 59 allograft rejection 59 Celecoxib 59 adrenalectomy 59 HMG CoA reductase inhibitors 59 PegIFN RBV 59 gefitinib 59 cilostazol 59 Procoralan 59 Contrast Induced Nephropathy 59 gadobutrol 59 endocrine therapy 59 alpha interferons 59 autoimmune reactions 59 intensive statin therapy 59 tamoxifen Nolvadex ® 59 osteosarcomas 59 Cimzia R 59 Fibrillex TM 59 spine fractures 59 VAPRISOL 59 low dose cytarabine 59 graft occlusion 59 ischemic stroke 59 Severe Primary IGFD 59 Camptosar ® 59 oxaliplatin Eloxatin 59 TTR gene 59 recurrent prostate cancer 59 mTOR inhibitors 59 acute ischemic stroke 59 transfusion transmitted 59 metachronous 59 hematological malignancy 59 Neoral 59 cilengitide 59 brain metastases 59 ribavirin RBV 59 forodesine 59 hypersensitivity reaction 59 FluCide